GLP-1s Explained: Beyond the Weightloss with Dr. Kimberly Ferrero

GLP-1 medications like Ozempic and Wegovy are making headlines for weight loss, but their potential impact goes far beyond the numbers on a scale. Could these drugs reshape health care spending, insurance coverage, longevity, and even the assumptions actuaries use to model risk?   In this episode of Actuary Voices, Contingencies Editor-in-Chief Preeti Vasishtha speaks with Dr. Kimberly Ferrero, the American Academy of Actuaries' Assistant Director of Research. Drawing on her background in cardiovascular and metabolic disease research, Dr. Ferrero explores the science behind GLP-1 therapies, the promises and uncertainties surrounding their long-term effects, and why actuaries are watching their rapid adoption so closely.  The conversation examines affordability, insurer costs, mortality assumptions, patient behavior, health equity, and the question at the center of today's debate: Will the impressive results seen in clinical trials translate into lasting improvements at the population level?   Additional Resources: Read Dr. Ferrero's article: How GLP-1 Drugs Are Shaping Care, Cost, and Coverage. Learn More About How Weightloss Drugs Effect Health care Costs in the Drivers of 2026 Premium Changes issue brief. Read Sam Gutterman's Last Word article on Weightloss Drugs, Weight and See?